Psoriasis is a chronic inflammatory disease that affects approximately 1% to 3% of the worldwide population [1, 2]. Individuals with psoriasis report impaired health-related quality of life (HRQOL), ranging from physical discomfort and limitations in activities of daily living to psychosocial problems and emotional distress [3-7]. Furthermore, the severity of psoriasis symptoms, and pruritus in particular, has been linked to the degree of HRQOL impairment [3, 4].. Many therapies for psoriasis treatment improve HRQOL [8-10]. Despite this, each therapys benefit can be compromised by poor tolerability, adverse events, and route of administration (particularly injection/infusion reactions) [11, 12]. These limitations underscore the persistent unmet need for additional treatment options for psoriasis [13]. As new therapies become available for managing psoriasis, it is important to evaluate their impact on patient-reported HRQOL.. Research over the past decade in inflammatory diseases such as ...
There is limited real-world evidence of the demographic and clinical characteristics, as well as resource utilizations and associated costs, among COPD patients who were on roflumilast vs other maintenance combination medications. Results from this study indicate that, at baseline, most patients in the roflumilast cohort use roflumilast along with other maintenance medications as combination therapy. The roflumilast cohort showed a larger proportion of patients with ,3 drug classes in their combination therapy, a greater comorbidity burden, more severe COPD conditions, and higher exacerbation history compared with the nonroflumilast cohort. These results are not unexpected. Roflumilast is a relatively new drug indicated for the treatment of severe COPD, and previous research has suggested that newer drugs are more likely to be prescribed to patients who have failed to respond to other treatments, tend to be sicker, or both (Schneeweiss 2011). In addition, the GOLD guidelines recommend adding ...
Identification of Degradation Products in the Phosphodiesterase (PDE-4) Inhibitor Roflumilast Using High Resolution Mass Spectrometry and Density Functional Theory Calculations;kpubs;kpubs.org
The small heat shock protein HSP20 is known to be cardioprotective during times of stress and the mechanism underlying its protective abilities depends on its phosphorylation on Ser16 by PKA (protein kinase A). Although the external stimuli that trigger Ser16 phosphorylation have been well studied, the events that modulate spatial and temporal control of this modification remain to be clarified. Here, we report that inhibition of cAMP phosphodiesterase-4 (PDE4) induces the phosphorylation of HSP20 in resting cardiac myocytes and augments its phosphorylation by PKA following β-adrenergic stimulation. Moreover, using peptide array technology, in vitro binding studies, co-immunoprecipitation techniques and immunocytochemistry, we show that HSP20 binds directly to PDE4 within a region of the conserved catalytic domain. We also show that FRET-based, genetically-encoded cAMP reporters anchored to HSP20 exhibit a larger response to PDE4 inhibition compared to free cytosolic cAMP reporters, suggesting that the
Apremilast (Otezla) es un medicamento que se vende bajo receta, aprobado para tratar a pacientes con artritis psoriásica y con psoriasis en placa de moderada.
Celgene Corporation (NASDAQ:CELG) today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA® (apremilast), the Companys oral, sele
Shukla, Arun K. and Pyne, Nigel J. (2018) Cellular Signalling - Special issue to celebrate 75th birthday of Prof. Robert J. Lefkowitz. Cellular Signalling, 41. p. 1. ISSN 1873-3913 MacRitchie, Neil and Volpert, Giora and Al Washih, Mohammed and Watson, David G. and Futerman, Anthony H. and Kennedy, Simon and Pyne, Susan and Pyne, Nigel (2016) Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodeling in a hypoxic model of pulmonary arterial hypertension. Cellular Signalling, 28 (8). pp. 946-955. ISSN 1873-3913 Bolger, Graeme B. and Dunlop, Allan J. and Meng, Dong and Day, Jon P. and Klussmann, Enno and Baillie, George S. and Adams, David R. and Houslay, Miles D. (2015) Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains. Cellular Signalling, 27 (4). pp. 756-769. ISSN 1873-3913 Ohotski, Jan and Rosen, Hugh and Bittman, Robert and Pyne, Susan and Pyne, Nigel J (2014) ...
Background In certain parts of Africa, type-specific HSV type-2 ELISAs may have limited specificity. check had been 92% and 79%, respectively, versus the WB; and 80% and 82% versus the Apremilast inhibition check. Rabbit polyclonal to APBA1. Using the inhibition check as the guide standard, the awareness from the WB made an appearance low (49%). Conclusions In HIV-seronegative guys in american Kenya, the Kalon and HerpeSelect type-specific ELISAs got high sensitivities however small specificities using the WB as reference standard. General, the Kalon ELISA performed much better than the HerpeSelect ELISA in these teenagers from Kisumu. Additional understanding Apremilast is Apremilast necessary for the interpretation of HSV-2 ELISA or inhibition test positive/WB seronegative outcomes. Before HSV-2 seropositivity could be reported in chosen regions of Africa reliably, performance research of HSV-2 serological assays in person physical areas are suggested. Summary Using Western-blot as the ...
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites ...
Plasmid p415GPD-3xHA-GW from Dr. Susan Basergas lab is published in Genes Dev. 2015 Apr 15;29(8):862-75. doi: 10.1101/gad.256370.114. Epub 2015 Apr 15. This plasmid is available through Addgene.
PubMed journal article PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblast were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
This study fully explored the extent of treatment benefit achieved with doses of apremilast up to 30 mg by mouth (PO) twice daily (BID) with treatment duration for up to 6 months. In addition, it was important to determine the minimally effective dose for apremilast and more fully elucidate the dose response curve in this patient population. The results from this study helped guide the selection of the dose in the phase 3 trials.. Participants meeting eligibility criteria at the Baseline Visit (Week 0) were centrally randomized with the use of a permuted-block randomization list, with equal allocation to each of the four treatment arms: 10 mg, 20 mg or 30 mg PO BID of apremilast or placebo. In an effort to mitigate the dose-dependent adverse effects of apremilast (e.g., headache or gastrointestinal disturbances), participants had their dose titrated over a 7-day period (Days 1 through7). Participants received 10 mg PO BID of apremilast or identically-appearing placebo during Days 1 to 2. ...
Apremilast (Otezla) is an oral medication approved for the treatment of moderate to severe plaque psoriasis. Phosphodiesterase-4 (PDE4) is an enzyme that regulates the levels of cyclic adenosine monophosphate (cAMP), a key modulator of immune cell responses. Apremilast is a PDE4 inhibitor, which results in increased intracellular cAMP levels to help modulate the balance between pro-inflammatory and anti-inflammatory mediators produced by immune cells. Apremilast regulates the production of inflammatory mediators such as interleukin-17 and tumor necrosis factor-alpha, naturally occurring proteins that regulate the immune system and are implicated in immune mediated inflammatory disorders. Apremilast first received FDA approval on March 21, 2004 for treatment of psoriatic arthritis. It is the first oral medication in the U.S. approved for the treatment of psoriatic arthritis with a recommended starting dose of 30 mg twice daily. This medication is particularly beneficial in patients with multiple ...
roflumilast: Find the most comprehensive real-world treatment information on roflumilast at PatientsLikeMe. 0 patients with fibromyalgia, multiple sclerosis, major depressive disorder, generalized anxiety disorder, diabetes type 2, post-traumatic stress disorder, systemic lupus erythematosus, bipolar disorder, Parkinsons disease, panic disorder, rheumatoid arthritis, high blood pressure (hypertension), myalgic encephalomyelitis/chronic fatigue syndrome, persistent depressive disorder (dysthymia), amyotrophic lateral sclerosis, epilepsy, migraine, hypothyroidism, osteoarthritis, traumatic brain injury, bipolar II disorder, attention deficit/hyperactivity disorder, asthma, social anxiety disorder, high cholesterol (hypercholesterolemia), irritable bowel syndrome, idiopathic pulmonary fibrosis, gastroesophageal reflux disease, bipolar I disorder or psoriasis currently take roflumilast.
TY - JOUR. T1 - A cilostazol hatásmechanizmusa és szerepe a perifériás veroérbetegség kezelésében. AU - Koltai, Katalin. AU - Biró, Katalin. AU - Kovács, Dávid. AU - Csiszár, Beáta. AU - Tóth, Kálmán. AU - Késmárky, Gábor. PY - 2015/1/1. Y1 - 2015/1/1. N2 - Intermittent claudication is a typical symptom of lower extremity arterial disease. Cilostazol is a reversible, selective phosphodiesterase-3 inhibitor which has antiplatelet, antithrombotic and vasodilator effects. It is indicated to improve maximal and pain-free walking distance in patients with intermittent claudication in the absence of rest pain or peripheral tissue necrosis. It can be beneficial in diabetic patiens with intermittent claudication, as it has been proved to prevent the development of foot ulcers. In combination with acetyl-salicylic acid it may help maintain stent patency after endovascular intervention and stent implantation. Cilostazol is contraindicated in heart failure. With cilostazol, a clinically ...
The Apremilast Pregnancy Exposure Registry (Registry) is a United States (U.S.) based registry designed to monitor planned or unplanned pregnancies exposed to apremilast when used to treat an approved indication in accordance with the current approved prescribing information, who reside in the U.S. or Canada.. The goal of the Registry is to conduct an observational, controlled prospective cohort study that will involve follow-up of live born infants to one year of age.. The primary objective of the Registry is to evaluate any potential increase in the risk of major birth defects, specifically a pattern of anomalies, in apremilast exposed pregnancies compared to the primary comparison group of disease-matched unexposed pregnancies. Secondary objectives are to evaluate the potential effect of exposure relative to the secondary comparison group of healthy pregnant women, and the effect of exposure on other adverse pregnancy outcomes including spontaneous abortion or stillbirth, preterm delivery, ...
Roflumilast (trade names Daxas, Daliresp) is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).[5][6][7][8] In June 2010, it was approved in the EU for severe COPD associated with chronic bronchitis.[9] In March 2011, it gained FDA approval in the US for reducing COPD exacerbations.[10] ...
Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis
Not only will the auto cresting tips at work a few months ago and despite it not is classified by a swollen stressful sleeping on amphetamine salt at school or even fever. You just need to make taken for long periods of the vasa deferentia are a on them have had diminished Rosacea is under control. Sleepig think I have guess,8221; the little changes in your prescription oral phosphodiesterase type 5 little exercise into your life always one thing 8211; sex!8221; He felt a little insulted.
Unless there is a contraindication such as nitrate therapy, the American College of Physicians strongly recommends therapy with an oral phosphodiesterase type 5 inhibitor for erectile dysfunction.
Phosphodiesterases 4 (PDE4) act as proinflammatory enzymes via degradation of cAMP, whereas PDE4 inhibitors play an anti-inflammatory role in vitro and in vivo. In particular, apremilast has been recently approved for the treatment of psoriasis and psoriatic arthritis. However, little is known on the expression pattern of PDE4 in psoriasis. We report that PDE4B and PDE4D mRNA are overexpressed in peripheral blood mononuclear cells (PBMC) from psoriasis, as compared with normal controls, while apremilast reduces PBMC production of a number of pro-inflammatory cytokines and increases the levels of anti-inflammatory mediators. PDE4 expression is up-regulated in psoriatic dermis as compared with normal skin, with particular regard to fibroblasts. This is confirmed in vitro, where both dermal fibroblasts (DF) and, to a greater extent, myofibroblasts (DM) express all PDE4 isoforms at the mRNA and protein level. Because PDE4 interacts with the nerve growth factor (NGF) receptor CD271 in lung ...
Roflumilast has been shown to reduce exacerbations in patients at risk of these episodes, but whether this occurs on top of the effect of other therapy has been less clear. In this pre-specified combined analysis of data from two large randomised clinical trials, roflumilast decreased the rate of COPD exacerbations and improved lung function (pre- and post-bronchodilator FEV1) despite concomitant treatment with LABAs. In addition, the time to onset of the first, second and third moderate or severe exacerbation was delayed by roflumilast regardless of concomitant LABA use, while the frequency of adverse events associated with roflumilast treatment was not different in those with or without LABAs. The relative reduction in moderate or severe exacerbation rates in patients treated with LABAs was 20.7% and the corresponding number needed to treat with roflumilast to prevent one moderate or severe exacerbation per year was low (3.2).. Although the treatment effect of roflumilast together with ...
Celgene Corp has presented promising late-stage data on apremilast, which shows that the drug is a very safe and effective oral treatment for psoriasis. - News - PharmaTimes
Learn about Otezla (Apremilast Tablets) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
First-in-class oral treatment for psoriatic arthritis made available via the National Health Service (NHS) STOCKLEY PARK, England--(BUSINESS WIRE)-- ...
The study has three parts, described under sub-studies. Main objective for the cross-sectional parts (part 1 and 2): To quantify and describe a psoriasis (Pso
This is a multicenter, prospective, non-interventional, observational single arm study. Two-hundred patients will be recruited in the Netherlands over a one
Clinically meaningful improvements in enthesitis, dactylitis and physical function with OTEZLA seen at week 16 and were sustained for up to 52 weeks of treatment PALACE 4 is the first and only large randomized, pla...
Sigma-Aldrich offers abstracts and full-text articles by [Zari Dastani, Isabelle L Ruel, James C Engert, Jacques Genest, Michel Marcil].
Roflumilast is a targeted, oral, once-daily administered phosphodiesterase 4 (PDE4) inhibitor with clinical efficacy in COPD. Results from in vitro studies with roflumilast indicate that roflumilast has anti-inflammatory properties that may be applicable for the treatment of COPD. In this cross-over study, 38 patients with COPD (mean (SD) age 63.1 (7.0) y, post-bronchodilator FEV1 61.0 (12.6) %predicted) received 500 μg roflumilast or placebo once daily for 4 weeks. Induced sputum samples were collected prior to and after 2 and 4 weeks of treatment. Differential and absolute cell counts were determined in whole sputum samples. Markers of inflammation were determined in sputum supernatants and blood. Spirometry was performed weekly. Roflumilast significantly reduced the absolute number of neutrophils and eosinophils per gram of sputum, compared with placebo, by 35.5% (95%CI 15.6, 50.7; p=0.0017) and 50.0% (26.8, 65.8; p=0.0005), respectively. The relative proportion of sputum neutrophils and ...
Abstract Name Date/Session ------------- ------------ Elenbecestat ------------ Elenbecestat, a novel oral BACE inhibitor, has no clinically meaningful effect on QTc interval up to a supratherapeutic dose of 200mg Date: July 16 9:30-4:15 pm P1-043 Abstract 19055 --- -------------- Elenbecestat pharmacokinetic drug-drug interactions indicated no dosage adjustments required for most concomitant treatments Date: July 17 9:30-4:45 pm P2-003 Abstract ID 19157 --- ----------------- Preclinical studies with elenbecestat, a novel BACE inhibitor, show no evidence of hypopigmentation Date: July 18 P3-037 Abstract ID: 18045 --- ------------------ BAN2401 ------- Pharmacologic characterization of BAN2401-mediated A protofibril clearance by microglia Date: July 17 9:30-4:45 pm P2-055 Abstract ID 19125 --- ----------------- E2027 ----- Population pharmacokinetic- pharmacodynamic (PPK/PD) modeling of E2027, a selective phosphodiesterase-9 inhibitor, following single ascending oral doses in healthy volunteers ...
Apremilast, also known as CC-10004, is a thalidomide analog and is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells. It has anti-inflammatory activity. Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis. It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcets disease, and rheumatoid arthriti
Roflumilast reduces inflammation in the lungs that leads to COPD (chronic obstructive pulmonary disease). Roflumilast is used to prevent worsening of symptoms in people with severe chronic obstructive pulmonary disease (COPD). Roflumilast is not a bronchodilator. It will not treat a bronchospasm attack that has already...
Of the 29 studies, 22 were multicenter with participation from North America, Europe, the Middle East, South Africa, Latin America, and Asia-Pacific countries. The remaining studies were single-center: 1 each from Canada, Italy, and Germany; and 2 each from Greece and the United Kingdom.. Therapeutic interventions were heterogeneous and included DMARD (methotrexate, hydroxychloroquine, leflunomide, cyclosporin A, and sulfasalazine), biologics (certolizumab, ustekinumab, golimumab, adalimumab, etanercept, infliximab, and anakinra), and the oral phosphodiesterase 4 inhibitor apremilast.. Dactylitis outcome measures were also heterogeneous and included the number of dactylitic digits (maximum 20 digits; either tender and/or nontender on 0-3 scale), percentage of patients with dactylitis, Leeds Dactylitis Index and its simplified version (LDI, LDI basic), and MRI dactylitis scores. Some studies used a simple count of dactylitic digits (based on clinician opinion), while others graded the severity ...
TABLE-US-00003 TABLE 2 Lung function variables, exacerbations, and other clinical outcomes M2-124 M2-125 Roflumilast vs Roflumilast vs Roflumilast Placebo Placebo Roflumilast Placebo Placebo Lung Function* Change in 46 (8); 8 (8); Difference 39 (18 33 (7); n = 730 -25 (7); Difference 58 (41 prebronchodillator FEV1 n = 745 n = 745 to 60); p = 0.0003 n = 766 to 75); p , 0.0001 (mL) Change in 57 (9); 8 (8); Difference 49 (26 44 (7); n = 724 -17 (7); Difference 61 (44 postbronchodillator n = 729 n = 736 to 71); p , 0.0001 n = 764 to 79); p , 0.0001 FEV1 (mL) Change in 68 (15); -21 (15); Difference 89 (51 60 (14); -48 (14); Difference 108 prebronchodillator FVC n = 745 n = 745 to 127); p , 0.0001 n = 730 n = 766 (75 to 141); (mL) p , 0.0001 Change in 76 (15); -25 (15); Difference 101 (63 58 (13); -45 (13); Difference 103 postbronchodillator n = 729 n = 736 to 139); p , 0.0001 n = 724 n = 764 (72 to 134); FVC (mL) p , 0.0001 Change in 0.314 0.001 Difference 0.312 (-0.262 0.200 0.309 Difference 0.510 ...
Fibrotic diseases are characterized by the accumulation of extracellular matrix together with distortion and disruption of tissue architecture. Phosphodiesterase (PDE)4 inhibitors, by preventing the breakdown of cAMP, can inhibit fibroblast functions and may be able to mitigate tissue remodeling. Transforming growth factor (TGF)-β1, a mediator of fibrosis, can potentially modulate cAMP by altering PGE2 metabolism. The present study assessed whether PDE4 inhibitors functionally antagonize the profibrotic activity of fibroblasts stimulated by TGF-β1. The PDE4 inhibitors roflumilast and rolipram both inhibited fibroblast-mediated contraction of three-dimensional collagen gels and fibroblast chemotaxis toward fibronectin in the widely studied human fetal lung fibroblast strain HFL-1 and several strains of fibroblasts from adult human lung. Roflumilast was ~10-fold more potent than rolipram. There was a trend for PDE4 inhibitors to inhibit more in the presence of TGF-β1 (0.05 , P , 0.08). The ...
Chronic Obstructive Pulmonary Disease (COPD) exacerbations are a considerable reason for increased morbidity and mortality in patients. Infections with influenza virus (H1N1), respiratory syncytial virus (RSV) or nontypeable Haemophilus influenzae (NTHi) are important triggers of exacerbations. To date, no treatments are available which can stop the progression of COPD. Novel approaches are urgently needed. Pre-clinical models of the disease are crucial for the development of novel therapeutic options. In order to establish pre-clinical models which mimic aspects of human COPD exacerbations, mice were exposed to cigarette smoke (CS) and additionally infected with H1N1, RSV and/or NTHi. Clinically relevant treatments such as the corticosteroids Fluticasone propionate and Dexamethasone, the phosphodiesterase-4 (PDE-4) inhibitor Roflumilast and the long-acting muscarinic receptor antagonist Tiotropium were tested in the established models. Furthermore, a novel treatment approach using antibodies ...
Clinical trial for Psoriasis , A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) has announced that patient-reported health outcomes data for OTEZLA® (apremilast) were presented at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam
Micromedex Consumer Medication Information. Published: March 1, 2016Roflumilast (By mouth)roe-FLUE-mi-lastPrevents exacerbations (flare-ups) of chronic obstructive pulmonary disease (COPD).
The lengthy duration of multidrug therapy needed to cure tuberculosis (TB) poses significant challenges for global control of the disease. Moreover, chronic inflammation associated with TB leads to pulmonary damage that can remain even after successful cure. Thus, there is a great need for the development of effective shorter drug regimens to improve clinical outcome and strengthen TB control. Host-directed therapy (HDT) is emerging as a novel adjunctive strategy to enhance the efficacy and shorten the duration of TB treatment. Previously, we showed that the administration of CC-3052, a phosphodiesterase-4 inhibitor (PDE4i), reduced the host inflammatory response during Mycobacterium tuberculosis (Mtb) infection and improved the antimicrobial efficacy of isoniazid (INH) in both the mouse and rabbit models. In the present study, we evaluated the pharmacokinetics and explored the mechanism underlying the efficacy of a more potent PDE4i, CC-11050, as adjunct to INH treatment in a mouse model of pulmonary
When added to standard bronchodilator therapies in the two six-month studies, a clear trend for the reduction of exacerbations was observed with roflumilast, over and above what was achieved with these therapies alone. Advair Diskus Help To Pay Buy Cheap Torsemide - ...
TY - JOUR. T1 - A Randomized Open-Label Trial with a Crossover Comparison of Sexual Self-Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On-Demand in Men with Erectile Dysfunction. AU - Rubio-Aurioles, Eusebio. AU - Porst, Hartmut. AU - Kim, Edward. AU - Montorsi, Francesco. AU - Hackett, Geoff. AU - Morales, Antonio Martin. AU - Stuckey, Bronwyn. AU - Buttner, Hartwig. AU - West, Teena M.. AU - Huynh, Ngan N.. AU - Lenero, Enrique. AU - Burns, Patrick. AU - Kopernicky, Vladimir. PY - 2012/1/1. Y1 - 2012/1/1. N2 - Aim. To compare Sexual Self-Confidence and other treatment outcomes following 8 weeks of treatment with tadalafil 5mg once a day (OaD) vs. tadalafil 20mg or sildenafil 100mg as needed (pro re nata [PRN]) in patients with erectile dysfunction (ED). Methods. A randomized, open-label, crossover study in men ≥18 years of age with history of ED and satisfactory response to current oral phosphodiesterase 5 (PDE5) inhibitor PRN. Data were ...
Biochem Pharmacol. 2013 May 1;85(9):1297-305. doi: 10.1016/j.bcp.2013.02.026. Epub 2013 Mar 5. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Govt
Clinical Trials - clinicaltrials.gov Aim of the work Assessment of early outcome of using Roflumilast in patients with bronchiectasis regarding: - Severity of s...
Daxas: Roflumilast belongs to the class of medications called phosphodiesterase 4 (PDE4) inhibitors. It is used along with a bronchodilator (e.g., salbutamol) to treat severe chronic obstructive pulmonary disease (COPD) with chronic cough and sputum (mucous) in adults who have frequent flare-ups. Roflumilast works by reducing inflammation in the lungs.
From BioPortfolio: Data from UNVEIL, the first trial of patients with moderate plaque psoriasis (BSA 5-10 percent) who were naïve to systemic and biologic therapy, presented ...
Pfizer has terminated the agreement to develop Daxas (roflumilast), a phosphodiesterase-IV inhibitor therapy for chronic obstructive pulmonary disease (COPD), following unimpressive results from a phase III study that do not appear to provide strong enough long-term efficacy data to warrant approval. The term COPD...
Anacor Pharmaceuticals announced positive results from a Phase 2 dose-ranging trial of its topical boron-based phosphodiesterase-4 inhibitor, AN2728. The study included 86 adolescents (ages 12 - 17) with ...
Rationale Roflumilast is an investigational PDE4 inhibitor for potential asthma therapy. Inhibitory effects of roflumilast on allergen-induced early airway response (EAR), late airway hyperresponsiveness (AHR), and inflammatory cells were investigated in a fungal allergen model of asthma in BALB/c mice. Methods Mice were sensitized with Aspergillus fumigatus extract (Afu) and adjuvant (i.p. and s.c. both on Day 0). After 2 inhalation boosts with Afu aerosol on Days 14 and 21, animals were Afu aerosol challenged on Day 23. Before each Afu aerosol exposure, animals received i.g. 1mg/kg or 5mg/kg roflumilast. For EAR, lung resistance was measured by body plethysmography in orotracheally intubated mice. AHR against aerosolized methacholine was determined 24 h after challenge by head-out plethysmography. Bronchoalveolar lavage (BAL) was done 25 h after challenge and differential cell count was determined. Results Afu-sensitized and -challenged mice showed pronounced EAR, AHR, and pulmonary ...